Pintado Claire, Delaugerre Constance, Molina Jean-Michel
Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France.
Department of Virology, Saint-Louis Hospital, University of Paris Diderot, Paris, France.
Open Forum Infect Dis. 2020 Sep 25;7(9):ofaa367. doi: 10.1093/ofid/ofaa367. eCollection 2020 Sep.
Maintenance antiretroviral therapy with combination of two injectable long-acting drugs, cabotegravir and rilpivirine, is a new strategy addressing the challenges of daily adherence to oral pills that has shown non-inferior efficacy to standard of care therapy in patients with suppressed HIV-infection. Patients co-infected with hepatitis B virus (HBV) are not eligible for this dual therapy since it has no activity against HBV, but this strategy should also be restricted to patients with anti-HBs antibodies since people with HIV are still at risk of HBV acquisition due to high risk behavior and since HBV vaccination does not always elicit anti-HBs antibodies, as highlighted in the case report below.
使用两种长效注射药物（卡博特韦和利匹韦林）联合进行的维持性抗逆转录病毒疗法，是应对每日口服药丸依从性挑战的一种新策略，在HIV感染得到抑制的患者中已显示出与标准护理疗法相当的疗效。合并感染乙型肝炎病毒（HBV）的患者不符合这种双重疗法的条件，因为它对HBV没有活性，但该策略也应仅限于具有抗-HBs抗体的患者，因为HIV感染者由于高危行为仍有感染HBV的风险，且如以下病例报告所强调的，HBV疫苗接种并不总是能引发抗-HBs抗体。
